Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026)
Compass Therapeutics (CMPX) posted Cash from Financing Activities of $3.4 million for Q1 2026, up 216.56% sequentially from $1.1 million in Q4 2025, and up 512.88% YoY from $549044.0 in Q1 2025.
Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 512.88% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.8 million (up 14802.09% YoY) and the FY2025 annual result came in at $129.6 million, up 647.54% from the prior year.
- Cash from Financing Activities improved to $3.4 million in Q1 2026 per CMPX's latest filing, from $1.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $129.4 million in Q3 2025 and troughed at -$815000.0 in Q1 2025.
- A 5-year average of $16.4 million and a median of $31000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 109.52% in 2024, then soared 6468150.0% in 2025.
- Over 5 years, Cash from Financing Activities stood at $75.8 million in 2022, then sank by 100.21% to -$158000.0 in 2023, then jumped by 40.51% to -$94000.0 in 2024, then surged by 1230.85% to $1.1 million in 2025, then jumped by 216.56% to $3.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.4 million, $1.1 million, and $129.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.37 Mn |
| Mar 31, 2026 | 3.37 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Sep 30, 2025 | 129.36 Mn |
| Mar 31, 2025 | -815,000.00 |
| Mar 31, 2025 | -815,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 17.43 Mn |
| Mar 31, 2024 | 17.43 Mn |
| Dec 31, 2023 | -158,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |